If you’ve been waiting on Australia’s patent box before you lock in an IP or tax strategy, stop waiting. It doesn’t exist. The government announced it in the 2021-22 Budget, introduced a bill in 2022, and let that bill die when the election was called. Nobody has brought it back since.
If you’re an Australian biotech, medtech, agtech or clean tech founder sitting on granted patents, that matters. There’s still advice floating around online that talks about the patent box as though it’s live and claimable. It isn’t. Here’s exactly what happened, and what to do with your IP and your R&D spend instead.
What the patent box was supposed to do
The 2021-22 Budget, handed down in May 2021, proposed a concessional 17% tax rate on income earned directly from Australian medical and biotechnology patents. That’s well under the standard company tax rate of 25% for base rate entities or 30% for everyone else.
The concession would only have applied to patents granted after the budget announcement on 11 May 2021, and only in proportion to how much of the underlying R&D happened in Australia. A company doing 80% of its research locally would get the 17% rate on 80% of the patent income, with the remaining 20% taxed at the normal rate. Manufacturing income and brand value stayed out of scope. Only royalty-style income and gains from licensing or selling the patent itself were ever going to qualify.
The following year’s budget extended the idea to agricultural technology and low emissions technology patents, with a proposed start date of 1 July 2023. The medical and biotech version was due to start a year earlier, on 1 July 2022.
On paper, this put Australia in line with a number of other countries that tax IP income at a lower rate to keep R&D and its commercial upside onshore instead of watching the patent get sold offshore once it’s valuable. The UK, Ireland and Singapore all run some version of a concessional regime for patent or IP income. Australia’s version got as far as two budget papers and a bill.
Why it never became law
Quick timeline
May 2021: the patent box is announced in the federal budget, covering medical and biotechnology patents.
February 2022: the enabling bill is introduced into Parliament.
March 2022: the following budget announces an extension to agricultural and low emissions technology patents, proposed to start 1 July 2023.
April 2022: the 2022 federal election is called. The bill lapses with every other bill still before Parliament.
May 2022 to now: no reintroduction, no new bill, no ATO guidance. Nothing has changed since the bill lapsed.
The bill that died with the election
The government introduced the enabling legislation, the Treasury Laws Amendment (Tax Concession for Australian Medical Innovations) Bill 2022, into Parliament in February 2022. It hadn’t passed by the time the 2022 federal election was called in April. Every bill still before Parliament when an election is called lapses, and the patent box bill was one of them.
No one picked it back up
The incoming government didn’t reintroduce it. There’s been no fresh budget commitment, no new bill, and no ATO guidance page, because there’s nothing for the ATO to administer. More than five years after the original announcement, the patent box is still just a line in two old budget papers and a bill that never got a vote.
Who this was ever going to help
Even if it had passed, the patent box was never going to be relevant to most Australian startups. The first version covered medical and biotechnology patents only. The extension covered agricultural technology and low emissions technology. SaaS, fintech, marketplaces, consumer apps and most hardware businesses were never in scope, regardless of what happened to the bill.
The companies that actually had something riding on this were the ones holding, or planning to hold, granted patents in those specific sectors, with real licensing or sale income expected to flow from them eventually. If that’s not you, the patent box was never going to change your tax position either way.
What this actually means if you hold IP
If you’ve structured a licensing arrangement, a cap table conversation or an IP holding entity around the assumption that patent income would eventually get a concessional rate, that assumption isn’t backed by any current law. Income from Australian patents is taxed the same as any other company income right now: 25% if you’re a base rate entity, 30% if you’re not. There’s no separate, lower rate sitting in reserve for the day the legislation turns up.
This hits medtech, biotech, agtech and clean tech companies hardest, since they’re the ones most likely to be holding granted patents and planning around eventually licensing or selling that IP. If your financial model has a line item assuming a 17% rate on future patent income, pull it out. It’s not real yet, and there’s no bill in Parliament that says it will be.
What’s actually available right now
None of this changes what’s already on offer, and the R&D Tax Incentive is the one that matters most to almost every founder reading this.
If you’re spending money on eligible R&D, companies with aggregated turnover under $20 million can get up to 43.5% of that spend back as a refundable cash offset, even while running at a loss. This is assessed on the R&D activity itself, not on whether you hold a patent. The test is technical uncertainty: did you try something where the outcome wasn’t known in advance, and did you have to work through failed attempts to get there.
A granted patent can be a reasonable sign that you did something novel enough to count as R&D, but the two are assessed completely separately by two different processes. You don’t need a patent to claim the RDTI, and holding one doesn’t automatically mean the work behind it qualifies either. Most companies claiming the RDTI never file a patent at all. The test is about the work, not the paperwork that might eventually sit on top of it.
If you want your IP taxed concessionally one day, the realistic path is claiming the R&D Tax Incentive every year on the work that creates that IP, not holding out for a scheme that’s been dead since 2022.
Will the patent box come back
Maybe. It keeps resurfacing in Australian innovation policy debate every time tax reform comes up. None of that is the same as a bill currently before Parliament. If it does eventually come back, the detail that will matter most is which patents qualify and from what date, not the headline rate. Businesses that assumed the 2021 rules would simply be revived got a reminder in 2022 that budget announcements and actual law are two different things.
The same caution applies to the R&D Tax Incentive right now. Proposed RDTI changes, a higher refundable turnover threshold, a higher minimum spend, and supporting activities losing automatic eligibility, moved from exposure draft to an actual bill before Parliament on 27 October 2026. That bill hasn’t passed yet, and the measures aren’t due to start until 1 July 2028 even if it does. The current RDTI rules, the ones in this article, are what apply today. Plan around what’s legislated, not around what’s been introduced or floated.
Until there’s a real bill moving through Parliament again, treat the patent box as what it is: an idea that didn’t make it into law.
Common questions
Is there any current Australian equivalent to a patent box?
No. There’s no live concessional tax rate for patent income in Australia. The R&D Tax Incentive is a separate program that refunds eligible R&D spend, not patent income, and it’s the closest thing to a comparable benefit available right now.
Does holding a patent help my R&D Tax Incentive claim?
Not directly. A patent application or grant can support your evidence that genuine technical uncertainty existed, but AusIndustry and the ATO assess the R&D activities themselves. You don’t need a patent to make a claim, and a patent alone doesn’t guarantee one qualifies.
Should I still file for patents if the tax break isn’t coming?
That’s a commercial IP decision, separate from tax. Patents protect your ability to stop competitors copying your invention and can matter for raising capital or an eventual sale, regardless of whether a concessional tax rate ever attaches to the income.
My accountant mentioned a patent box concession. Should I claim it?
Be careful with this one. If anyone suggests applying a concessional rate to patent income on a current tax return, that’s not supported by any current law and isn’t something the ATO will recognise. Flag it and ask exactly what they’re referring to before it goes anywhere near a lodged return.
The practical move
Don’t restructure anything around a patent box that doesn’t exist. Keep claiming the R&D Tax Incentive on the development work that generates your IP in the first place. That’s the refund actually available to you every financial year, right now, not a maybe sitting in a five-year-old budget paper.
If you’re not sure whether your current R&D activities would qualify, or you want a second opinion on what you’re claiming versus what you could be claiming, book a quick chat with us at granton.io/meet. We only take on claims we’re confident in, and we’ll tell you straight if there isn’t one worth making.
Are you ready to turn your funding aspirations into reality? At Granton, we specialize in helping individuals and businesses navigate the world of grants, offering expert guidance on grant applications and finding opportunities that best suit their needs. Whether you’re seeking funding for a startup, nonprofit, or a specific project, our team is here to assist you every step of the way. We take the guesswork out of Grant Applications, R&D Tax Incentives, and Accelerator Programs, making the process smoother and increasing your chances of success. Ready to take the next step? Book a free consultation with us today, and let’s explore how we can help you secure the grants you deserve. Visit our website at granton.io to learn more or use our contact form to get in touch. Your grant journey starts here!